JP2001523267A - 多発性嚢胞腎の治療のためのキナゾリン化合物の使用 - Google Patents
多発性嚢胞腎の治療のためのキナゾリン化合物の使用Info
- Publication number
- JP2001523267A JP2001523267A JP54816098A JP54816098A JP2001523267A JP 2001523267 A JP2001523267 A JP 2001523267A JP 54816098 A JP54816098 A JP 54816098A JP 54816098 A JP54816098 A JP 54816098A JP 2001523267 A JP2001523267 A JP 2001523267A
- Authority
- JP
- Japan
- Prior art keywords
- amino
- bromophenyl
- quinazolinyl
- carbons
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.それを必要とする哺乳動物の多発性嚢胞腎を治療または阻害する方法であ って、該哺乳動物に式: [式中、Xは、所望により、ハロゲン、炭素数1〜6のアルキル、炭素数1〜6 のアルコキシ、ヒドロキシ、トリフルオロメチル、シアノ、ニトロ、カルボキシ 、炭素数2〜7のカルボアルコキシ、炭素数2〜7のカルボアルキル、アミノ、 および炭素数1〜6のアルカノイルアミノから選択される1個またはそれ以上の 置換基で置換されていてもよいフェニル; RおよびR1は、各々独立して、水素、ハロゲン、炭素数1〜6のアルキル、 炭素数1〜6のアルコキシ、ヒドロキシ、またはトリフルオロメチル; R2は、水素、炭素数1〜6のアルキル、炭素数1〜6のアルコキシ、ヒドロ キシ、またはトリフルオロメチル; Yは、下記のものから選択される基: R3は、独立して、水素、炭素数1〜6のアルキル、カルボキシ、炭素数1〜 6のカルボアルコキシ、フェニル、または炭素数2〜7のカルボアルキル; n=2〜4; ただし、Yの各R3は同一であっても相異なっていてもよい] で示される化合物またはその医薬上許容される塩を投与することからなる方法。 2.R、R1、およびR2が水素またはその医薬上許容される塩である請求項1 記載の方法。 3.Xが無置換であるか、あるいはハロゲンまたは炭素数1〜6のアルキルで 置換されている請求項2記載の方法。 4.N-[4-[(3-ブロモフェニル)アミノ]-6-キナゾリニル]-2-ブチンアミ ドまたはその医薬上許容される塩が投与される請求項1記載の方法。 5.N-[4-[(3-ブロモフェニル)アミノ]-6-キナゾリニル]-2-メチル-2- プロペンアミドまたはその医薬上許容される塩が投与される請求項1記載の方法 。 6.N-[4-[(3-ブロモフェニル)アミノ]-6-キナゾリニル]-2,4-ヘキサジ エンアミドまたはその医薬上許容される塩が投与される請求項1記載の方法。 7.N-[4-[(3-ブロモフェニル)アミノ]-6-キナゾリニル]-(E)-2-ブテン アミドまたはその医薬上許容される塩が投与される請求項1記載の方法。 8.N-[4-[(3-ブロモフェニル)アミノ]-6-キナゾリニル]-3-メチル-2- ブテンアミドまたはその医薬上許容される塩が投与される請求項1記載の方法。 9.4-[[4-[(3-ブロモフェニル)アミノ]-6-キナゾリニル]アミノ]-4-オ キソ-(Z)-2-ブテン酸またはその医薬上許容される塩が投与される請求項1記 載の方法。 10.4-[[4-[(3-ブロモフェニル)アミノ]-6-キナゾリニル]アミノ]-4- オキソ-(E)-2-ブテン酸またはその医薬上許容される塩が投与される請求項1 記載の方法。 11.4-[[4-[(3-ブロモフェニル)アミノ]-6-キナゾリニル]アミノ]-4- オキソ-(E)-2-ブテン酸エチルエステルまたはその医薬上許容される塩が投与さ れる請求項1記載の方法。 12.N-[4-[(3-ブロモフェニル)アミノ]-6-キナゾリニル]-2-シクロペ ンテンアミドまたはその医薬上許容される塩が投与される請求項1記載の方法。 13.N-[4-[(3-ブロモフェニル)アミノ]-6-キナゾリニル]-2-プロペン アミドまたはその医薬上許容される塩が投与される請求項1記載の方法。 14.N-[4-[(3-ブロモフェニル)アミノ]-6-キナゾリニル]-(3-フェニ ル-2-プロピンアミド)またはその医薬上許容される塩が投与される請求項1記 載の方法。 15.哺乳動物の腎疾患を治療または阻害する医薬品の製造における式1: [式中、Xは、所望により、ハロゲン、炭素数1〜6のアルキル、炭素数1〜6 のアルコキシ、ヒドロキシ、トリフルオロメチル、シアノ、ニトロ、カルボキシ 、炭素数2〜7のカルボアルコキシ、炭素数2〜7のカルボアルキル、アミノ、 および炭素数1〜6のアルカノイルアミノからなる群から選択される1個または それ以上の置換基で置換されていてもよいフェニル; RおよびR1は、各々独立して、水素、ハロゲン、炭素数1〜6のアルキル、 炭素数1〜6のアルコキシ、ヒドロキシ、またはトリフルオロメチル; R2は、水素、炭素数1〜6のアルキル、炭素数1〜6のアルコキシ、ヒドロ キシ、またはトリフルオロメチル; Yは、 からなる群から選択される基] で示される化合物の使用。 16.R、R1、およびR2が水素またはその医薬上許容される塩である請求項 15記載の使用。 17.Xが無置換であるか、あるいはハロゲンまたは炭素数1〜6のアルキル で置換されている請求項15または請求項16記載の使用。 18.化合物が下記のうちの一つまたはその医薬上許容される塩である請求項 15記載の使用: N-[4-[(3-ブロモフェニル)アミノ]-6-キナゾリニル]-2-ブチンアミド; N-[4-[(3-ブロモフェニル)アミノ]-6-キナゾリニル]-2-メチル-2-プロ ペンアミド; N-[4-[(3-ブロモフェニル)アミノ]-6-キナゾリニル]-2,4-ヘキサジエン アミド; N-[4-[(3-ブロモフェニル)アミノ]-6-キナゾリニル]-(E)-2-ブテンアミ ド; N-[4-[(3-ブロモフェニル)アミノ]-6-キナゾリニル]-3-メチル-2-ブテ ンアミド; 4-[[4-[(3-ブロモフェニル)アミノ]-6-キナゾリニル]アミノ]-4-オキソ- (Z)-2-ブテン酸; 4-[[4-[(3-ブロモフェニル)アミノ]-6-キナゾリニル]アミノ]-4-オキソ- (E)-2-ブテン酸; 4-[[4-[(3-ブロモフェニル)アミノ]-6-キナゾリニル]アミノ]-4-オキソ- (E)-2-ブテン酸エチルエステル; N-[4-[(3-ブロモフェニル)アミノ]-6-キナゾリニル]-2-シクロペンテン アミド; N-[4-[(3-ブロモフェニル)アミノ]-6-キナゾリニル]-2-プロペンアミド ;および N-[4-[(3-ブロモフェニル)アミノ]-6-キナゾリニル]-(3-フェニル-2-プ ロピンアミド)。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85226697A | 1997-05-06 | 1997-05-06 | |
US08/852,266 | 1997-05-06 | ||
PCT/US1998/008482 WO1998050038A1 (en) | 1997-05-06 | 1998-04-28 | Use of quinazoline compounds for the treatment of polycystic kidney disease |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001523267A true JP2001523267A (ja) | 2001-11-20 |
JP4327259B2 JP4327259B2 (ja) | 2009-09-09 |
Family
ID=25312893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54816098A Expired - Fee Related JP4327259B2 (ja) | 1997-05-06 | 1998-04-28 | 多発性嚢胞腎の治療のためのキナゾリン化合物の使用 |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0980244B1 (ja) |
JP (1) | JP4327259B2 (ja) |
CN (1) | CN1195521C (ja) |
AR (1) | AR012660A1 (ja) |
AT (1) | ATE241986T1 (ja) |
AU (1) | AU7165698A (ja) |
CA (1) | CA2288705C (ja) |
DE (1) | DE69815340T2 (ja) |
DK (1) | DK0980244T3 (ja) |
ES (1) | ES2201484T3 (ja) |
HK (1) | HK1025262A1 (ja) |
PT (1) | PT980244E (ja) |
WO (1) | WO1998050038A1 (ja) |
ZA (1) | ZA983731B (ja) |
Families Citing this family (143)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
PT1676845E (pt) | 1999-11-05 | 2008-08-05 | Astrazeneca Ab | Novos derivados de quinazolina |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
GB0309850D0 (en) | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
AU2004291709C1 (en) | 2003-05-30 | 2010-03-11 | Astrazeneca Uk Limited | Process |
GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
CN1972688B (zh) | 2004-05-06 | 2012-06-27 | 沃尼尔·朗伯有限责任公司 | 4-苯胺基-喹唑啉-6-基-酰胺类化合物 |
ATE501148T1 (de) | 2004-12-14 | 2011-03-15 | Astrazeneca Ab | Pyrazolopyrimidinverbindungen als antitumormittel |
WO2007034144A1 (en) | 2005-09-20 | 2007-03-29 | Astrazeneca Ab | 4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer |
CA2662236A1 (en) | 2006-09-12 | 2008-03-20 | Genentech, Inc. | Methods and compositions for the diagnosis and treatment of cancer |
EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
CA2677336A1 (en) | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
KR20100111291A (ko) | 2008-02-07 | 2010-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 스피로사이클릭 헤테로사이클, 상기 화합물을 함유하는 약제, 이의 용도 및 이의 제조 방법 |
CN102088979B (zh) | 2008-05-13 | 2013-10-16 | 阿斯利康(瑞典)有限公司 | 4-(3-氯-2-氟苯胺基)-7-甲氧基-6-{[1-(n-甲基氨基甲酰基甲基)哌啶-4-基]氧基}喹唑啉的富马酸盐 |
CA2733153C (en) | 2008-08-08 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
EP2408817B1 (en) | 2009-03-20 | 2016-03-16 | F.Hoffmann-La Roche Ag | Bispecific anti-her antibodies |
KR20120103587A (ko) | 2009-11-12 | 2012-09-19 | 제넨테크, 인크. | 수상돌기 소극 밀도를 증진시키는 방법 |
AR079984A1 (es) | 2010-01-12 | 2012-03-07 | Hoffmann La Roche | Compuestos heterociclicos triciclicos, composiciones y su uso en el tratamiento de enfermedades mediadas por la inhibicion de jak1 |
US9556249B2 (en) | 2010-02-18 | 2017-01-31 | Genentech, Inc. | Neuregulin antagonists and use thereof in treating cancer |
US20130096104A1 (en) | 2010-03-17 | 2013-04-18 | Genentech, Inc. | Imidazopyridine compounds, compositions and methods of use |
BR112012026470A2 (pt) | 2010-04-16 | 2016-08-09 | Genentech Inc | método para prever a sensibilidade de crescimento de células tumorais e para tratar um tumor em um paciente |
JP2013537966A (ja) | 2010-08-31 | 2013-10-07 | ジェネンテック, インコーポレイテッド | バイオマーカー及び治療の方法 |
CN103209695A (zh) | 2010-09-15 | 2013-07-17 | 弗·哈夫曼-拉罗切有限公司 | 氮杂苯并噻唑化合物、组合物及应用方法 |
BR112013011520A2 (pt) | 2010-11-19 | 2019-09-24 | Hoffmann La Roche | pirazolo piridinas e pirazolo piridinas e seu uso como inibidores de tyk2 |
WO2012085176A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors |
WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
WO2013007765A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
KR20140047160A (ko) | 2011-08-12 | 2014-04-21 | 에프. 호프만-라 로슈 아게 | 인다졸 화합물, 조성물 및 사용 방법 |
CA2842375A1 (en) | 2011-08-17 | 2013-02-21 | Erica Jackson | Neuregulin antibodies and uses thereof |
CA2845409A1 (en) | 2011-09-20 | 2013-03-28 | Yingjie Lai | Imidazopyridine compounds, compositions and methods of use |
CA2857114A1 (en) | 2011-11-30 | 2013-06-06 | Genentech, Inc. | Erbb3 mutations in cancer |
CA2865082A1 (en) | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
BR112015018418A2 (pt) | 2013-02-22 | 2017-07-18 | Hoffmann La Roche | métodos para tratar câncer, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir o desenvolvimento de câncer, para aumentar a sensibilidade a um terapêutico direcionado, para estender o período de sensibilidade, para estender a duração de resposta a um terapêutico direcionado e produto farmacêutico |
MX2015011428A (es) | 2013-03-06 | 2016-02-03 | Genentech Inc | Metodos para tratar y prevenir la resistencia a los farmacos para el cancer. |
EP2970307B1 (en) | 2013-03-13 | 2020-03-11 | Genentech, Inc. | Pyrazolo compounds and uses thereof |
KR20150127216A (ko) | 2013-03-14 | 2015-11-16 | 제넨테크, 인크. | 암의 치료 및 암 약물 내성의 예방 방법 |
KR20150127203A (ko) | 2013-03-14 | 2015-11-16 | 제넨테크, 인크. | Mek 억제제 화합물과 her3/egfr 억제제 화합물의 조합물 및 사용 방법 |
CA2905123A1 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
MX2016002794A (es) | 2013-09-05 | 2016-09-13 | Genentech Inc | Compuestos antiproliferativos. |
WO2015049325A1 (en) | 2013-10-03 | 2015-04-09 | F. Hoffmann-La Roche Ag | Therapeutic inhibitors of cdk8 and uses thereof |
JP6677638B2 (ja) | 2013-10-18 | 2020-04-08 | ジェネンテック, インコーポレイテッド | 抗rspo2及び/又はrspo3抗体及びそれらの使用 |
AU2014364606A1 (en) | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists |
EP3083692B1 (en) | 2013-12-17 | 2020-02-19 | F.Hoffmann-La Roche Ag | Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies |
CN107002119A (zh) | 2014-03-24 | 2017-08-01 | 豪夫迈·罗氏有限公司 | 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联 |
KR20160145624A (ko) | 2014-03-31 | 2016-12-20 | 제넨테크, 인크. | 항-ox40 항체 및 사용 방법 |
RU2016142476A (ru) | 2014-03-31 | 2018-05-07 | Дженентек, Инк. | Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40 |
JP6814730B2 (ja) | 2014-09-05 | 2021-01-20 | ジェネンテック, インコーポレイテッド | 治療用化合物およびその使用 |
WO2016044694A1 (en) | 2014-09-19 | 2016-03-24 | Genentech, Inc. | Use of cbp/ep300 and bet inhibitors for treatment of cancer |
EP3204379B1 (en) | 2014-10-10 | 2019-03-06 | Genentech, Inc. | Pyrrolidine amide compounds as histone demethylase inhibitors |
AU2015343339A1 (en) | 2014-11-03 | 2017-06-15 | Genentech, Inc. | Methods and biomarkers for predicting efficacy and evaluation of an OX40 agonist treatment |
WO2016073378A1 (en) | 2014-11-03 | 2016-05-12 | Genentech, Inc. | Assays for detecting t cell immune subsets and methods of use thereof |
RU2017119428A (ru) | 2014-11-06 | 2018-12-06 | Дженентек, Инк. | Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit |
JP6639497B2 (ja) | 2014-11-10 | 2020-02-05 | ジェネンテック, インコーポレイテッド | ブロモドメインインヒビターおよびその使用 |
MA40940A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
MA40943A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
EP3221360A1 (en) | 2014-11-17 | 2017-09-27 | F. Hoffmann-La Roche AG | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
JP6771464B2 (ja) | 2014-11-27 | 2020-10-21 | ジェネンテック, インコーポレイテッド | Cbpおよび/またはep300インヒビターとしての、4,5,6,7−テトラヒドロ−1h−ピラゾロ[4,3−c]ピリジン−3−アミン化合物 |
AU2015369624A1 (en) | 2014-12-23 | 2017-06-08 | Genentech, Inc. | Compositions and methods for treating and diagnosing chemotherapy-resistant cancers |
CN107208138A (zh) | 2014-12-30 | 2017-09-26 | 豪夫迈·罗氏有限公司 | 用于癌症预后和治疗的方法和组合物 |
EP3242874B1 (en) | 2015-01-09 | 2018-10-31 | Genentech, Inc. | Pyridazinone derivatives and their use in the treatment of cancer |
WO2016112251A1 (en) | 2015-01-09 | 2016-07-14 | Genentech, Inc. | 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors |
EP3242872B1 (en) | 2015-01-09 | 2019-07-03 | Genentech, Inc. | (piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer |
EP3250571B1 (en) | 2015-01-29 | 2022-11-30 | Genentech, Inc. | Therapeutic compounds and uses thereof |
CN107438593B (zh) | 2015-01-30 | 2020-10-30 | 基因泰克公司 | 治疗化合物及其用途 |
MA41598A (fr) | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
CN107709364A (zh) | 2015-04-07 | 2018-02-16 | 豪夫迈·罗氏有限公司 | 具有激动剂活性的抗原结合复合体及使用方法 |
SI3294770T1 (sl) | 2015-05-12 | 2021-01-29 | F. Hoffmann-La Roche Ag | Terapevtski in diagnostični postopki za raka |
MX2017014736A (es) | 2015-05-29 | 2018-03-23 | Genentech Inc | Metodos terapeuticos y diagnosticos para cancer. |
WO2016200836A1 (en) | 2015-06-08 | 2016-12-15 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies |
MX2017015937A (es) | 2015-06-08 | 2018-12-11 | Genentech Inc | Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1. |
KR20180018538A (ko) | 2015-06-17 | 2018-02-21 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법 |
PL3341376T3 (pl) | 2015-08-26 | 2021-08-02 | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Skondensowane związki tricykliczne jako inhibitory kinaz białkowych |
MX2018003633A (es) | 2015-09-25 | 2018-08-01 | Genentech Inc | Anticuerpos anti-tigit y metodos de uso. |
HRP20220227T1 (hr) | 2015-12-16 | 2022-04-29 | Genentech, Inc. | Postupak priprave tricikličnih spojeva inhibitora p13k i postupci upotrebe navedenih spojeva u liječenju raka |
KR20180097615A (ko) | 2016-01-08 | 2018-08-31 | 에프. 호프만-라 로슈 아게 | Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법 |
CN109196121B (zh) | 2016-02-29 | 2022-01-04 | 基因泰克公司 | 用于癌症的治疗和诊断方法 |
EP3865511A1 (en) | 2016-04-14 | 2021-08-18 | F. Hoffmann-La Roche AG | Anti-rspo3 antibodies and methods of use |
JP2019518426A (ja) | 2016-04-15 | 2019-07-04 | ジェネンテック, インコーポレイテッド | がんの診断及び治療方法 |
WO2017181111A2 (en) | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Methods for monitoring and treating cancer |
AU2017248766A1 (en) | 2016-04-15 | 2018-11-01 | Genentech, Inc. | Methods for monitoring and treating cancer |
CN109476663B (zh) | 2016-05-24 | 2021-11-09 | 基因泰克公司 | 用于治疗癌症的吡唑并吡啶衍生物 |
CN115028617A (zh) | 2016-05-24 | 2022-09-09 | 基因泰克公司 | Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途 |
CN109312407A (zh) | 2016-06-08 | 2019-02-05 | 豪夫迈·罗氏有限公司 | 用于癌症的诊断和治疗方法 |
US11046776B2 (en) | 2016-08-05 | 2021-06-29 | Genentech, Inc. | Multivalent and multiepitopic antibodies having agonistic activity and methods of use |
WO2018029124A1 (en) | 2016-08-08 | 2018-02-15 | F. Hoffmann-La Roche Ag | Therapeutic and diagnostic methods for cancer |
CN110418851A (zh) | 2016-10-06 | 2019-11-05 | 基因泰克公司 | 癌症的治疗和诊断方法 |
JP2019535250A (ja) | 2016-10-29 | 2019-12-12 | ジェネンテック, インコーポレイテッド | 抗mic抗体及び使用方法 |
JP7256127B2 (ja) | 2017-03-01 | 2023-04-11 | ジェネンテック, インコーポレイテッド | がんのための診断及び治療方法 |
KR20190136076A (ko) | 2017-04-13 | 2019-12-09 | 에프. 호프만-라 로슈 아게 | 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제 |
JP2020532982A (ja) | 2017-09-08 | 2020-11-19 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんの診断及び治療方法 |
EP3710001A4 (en) | 2017-10-27 | 2021-07-14 | University Of Virginia Patent Foundation | COMPOUNDS AND PROCEDURES FOR REGULATING, LIMITING OR INHIBITING AVIL EXPRESSION |
CN111213059B (zh) | 2017-11-06 | 2024-01-09 | 豪夫迈·罗氏有限公司 | 用于癌症的诊断和治疗方法 |
EP3797173A2 (en) | 2018-05-21 | 2021-03-31 | Nanostring Technologies, Inc. | Molecular gene signatures and methods of using same |
MA52968A (fr) | 2018-06-23 | 2021-04-28 | Hoffmann La Roche | Méthodes de traitement du cancer du poumon à l'aide d'un antagoniste de liaison à l'axe pd-1, d'un agent de platine et d'un inhibiteur de la topoisomérase ii |
BR112021000673A2 (pt) | 2018-07-18 | 2021-04-20 | Genentech, Inc. | métodos para tratar um indivíduo com câncer de pulmão, kits, anticorpo anti-pd-l1 e composições |
TW202024023A (zh) | 2018-09-03 | 2020-07-01 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
WO2020061060A1 (en) | 2018-09-19 | 2020-03-26 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
EP4249917A3 (en) | 2018-09-21 | 2023-11-08 | F. Hoffmann-La Roche AG | Diagnostic methods for triple-negative breast cancer |
KR20210079311A (ko) | 2018-10-18 | 2021-06-29 | 제넨테크, 인크. | 육종성 신장암에 대한 진단과 치료 방법 |
JP2022519649A (ja) | 2019-02-08 | 2022-03-24 | ジェネンテック, インコーポレイテッド | がんの診断および治療方法 |
SG11202108707WA (en) | 2019-02-27 | 2021-09-29 | Epiaxis Therapeutics Pty Ltd | Methods and agents for assessing t-cell function and predicting response to therapy |
MX2021010313A (es) | 2019-02-27 | 2021-09-23 | Genentech Inc | Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38. |
WO2020223233A1 (en) | 2019-04-30 | 2020-11-05 | Genentech, Inc. | Prognostic and therapeutic methods for colorectal cancer |
AU2020270376A1 (en) | 2019-05-03 | 2021-10-07 | Genentech, Inc. | Methods of treating cancer with an anti-PD-L1 antibody |
CN112300279A (zh) | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | 针对抗cd73抗体和变体的方法和组合物 |
EP4025608A1 (en) | 2019-09-04 | 2022-07-13 | F. Hoffmann-La Roche AG | Cd8 binding agents and uses thereof |
WO2021062085A1 (en) | 2019-09-27 | 2021-04-01 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
US20230024096A1 (en) | 2019-10-29 | 2023-01-26 | Hoffmann-La Roche Inc. | Bifunctional compounds for the treatment of cancer |
WO2021092171A1 (en) | 2019-11-06 | 2021-05-14 | Genentech, Inc. | Diagnostic and therapeutic methods for treatment of hematologic cancers |
WO2021097110A1 (en) | 2019-11-13 | 2021-05-20 | Genentech, Inc. | Therapeutic compounds and methods of use |
CN117417448A (zh) | 2019-12-13 | 2024-01-19 | 基因泰克公司 | 抗ly6g6d抗体及使用方法 |
WO2021127404A1 (en) | 2019-12-20 | 2021-06-24 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
WO2021194481A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
TW202142230A (zh) | 2020-01-27 | 2021-11-16 | 美商建南德克公司 | 用於以抗tigit拮抗體抗體治療癌症之方法 |
WO2021177980A1 (en) | 2020-03-06 | 2021-09-10 | Genentech, Inc. | Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist |
CN115698717A (zh) | 2020-04-03 | 2023-02-03 | 基因泰克公司 | 癌症的治疗和诊断方法 |
WO2021222167A1 (en) | 2020-04-28 | 2021-11-04 | Genentech, Inc. | Methods and compositions for non-small cell lung cancer immunotherapy |
AU2021293038A1 (en) | 2020-06-16 | 2023-02-02 | F. Hoffmann-La Roche Ag | Methods and compositions for treating triple-negative breast cancer |
EP4168118A1 (en) | 2020-06-18 | 2023-04-26 | Genentech, Inc. | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
EP4189121A1 (en) | 2020-08-03 | 2023-06-07 | Genentech, Inc. | Diagnostic and therapeutic methods for lymphoma |
WO2022036146A1 (en) | 2020-08-12 | 2022-02-17 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
US20220119409A1 (en) | 2020-09-23 | 2022-04-21 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
EP4225443A1 (en) | 2020-10-05 | 2023-08-16 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
CR20230382A (es) | 2021-02-12 | 2023-09-06 | Hoffmann La Roche | Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer |
EP4347603A1 (en) | 2021-05-25 | 2024-04-10 | Erasca, Inc. | Sulfur-containing heteroaromatic tricyclic kras inhibitors |
WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
EP4384522A1 (en) | 2021-08-10 | 2024-06-19 | Erasca, Inc. | Selective kras inhibitors |
WO2023097194A2 (en) | 2021-11-24 | 2023-06-01 | Genentech, Inc. | Therapeutic compounds and methods of use |
TW202332429A (zh) | 2021-11-24 | 2023-08-16 | 美商建南德克公司 | 治療性化合物及其使用方法 |
WO2023191816A1 (en) | 2022-04-01 | 2023-10-05 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023219613A1 (en) | 2022-05-11 | 2023-11-16 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
WO2024015897A1 (en) | 2022-07-13 | 2024-01-18 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024020432A1 (en) | 2022-07-19 | 2024-01-25 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024033388A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024033457A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024033458A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydroazepine derivatives |
WO2024033389A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024085242A2 (en) | 2022-10-21 | 2024-04-25 | Kawasaki Institute Of Industrial Promotion | Non-fouling or super stealth vesicle |
WO2024091991A1 (en) | 2022-10-25 | 2024-05-02 | Genentech, Inc. | Therapeutic and diagnostic methods for multiple myeloma |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9314893D0 (en) * | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
TW321649B (ja) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd |
-
1998
- 1998-04-28 CA CA002288705A patent/CA2288705C/en not_active Expired - Fee Related
- 1998-04-28 DE DE69815340T patent/DE69815340T2/de not_active Expired - Fee Related
- 1998-04-28 WO PCT/US1998/008482 patent/WO1998050038A1/en active IP Right Grant
- 1998-04-28 PT PT98918802T patent/PT980244E/pt unknown
- 1998-04-28 CN CNB988048388A patent/CN1195521C/zh not_active Expired - Fee Related
- 1998-04-28 ES ES98918802T patent/ES2201484T3/es not_active Expired - Lifetime
- 1998-04-28 EP EP98918802A patent/EP0980244B1/en not_active Expired - Lifetime
- 1998-04-28 DK DK98918802T patent/DK0980244T3/da active
- 1998-04-28 AU AU71656/98A patent/AU7165698A/en not_active Abandoned
- 1998-04-28 JP JP54816098A patent/JP4327259B2/ja not_active Expired - Fee Related
- 1998-04-28 AT AT98918802T patent/ATE241986T1/de not_active IP Right Cessation
- 1998-05-04 ZA ZA9803731A patent/ZA983731B/xx unknown
- 1998-05-05 AR ARP980102087A patent/AR012660A1/es unknown
-
2000
- 2000-07-26 HK HK00104650A patent/HK1025262A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ATE241986T1 (de) | 2003-06-15 |
DE69815340T2 (de) | 2004-05-06 |
WO1998050038A1 (en) | 1998-11-12 |
CN1195521C (zh) | 2005-04-06 |
EP0980244A1 (en) | 2000-02-23 |
ES2201484T3 (es) | 2004-03-16 |
CA2288705C (en) | 2008-03-18 |
EP0980244B1 (en) | 2003-06-04 |
HK1025262A1 (en) | 2000-11-10 |
AU7165698A (en) | 1998-11-27 |
CA2288705A1 (en) | 1998-11-12 |
DE69815340D1 (de) | 2003-07-10 |
PT980244E (pt) | 2003-10-31 |
AR012660A1 (es) | 2000-11-08 |
ZA983731B (en) | 1999-11-04 |
CN1255062A (zh) | 2000-05-31 |
JP4327259B2 (ja) | 2009-09-09 |
DK0980244T3 (da) | 2003-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001523267A (ja) | 多発性嚢胞腎の治療のためのキナゾリン化合物の使用 | |
US5929080A (en) | Method of treating polycystic kidney disease | |
EP1378247B1 (en) | Visual function disorder improving agents | |
JP2001522802A (ja) | 大腸ポリープを治療するためのチロシンキナーゼインヒビターとしてのキナゾリン誘導体の使用 | |
JPH09507219A (ja) | α−2−アドレノセプター作動剤として有用な7−(2−イミダゾリニルアミノ)キノリン化合物 | |
EP2242738B1 (de) | Sgk1-inhibitoren zur prophylaxe und/oder therapie von viralen erkrankungen und/oder karzinomen | |
DE202011110043U1 (de) | Mehrkomponentensystem von Rosuvastatin-Calciumsalz und Sorbit | |
DE202012011888U1 (de) | Kristallines Mehrkomponentensystem von Rosuvastatin-Calciumsalz und Vanillin | |
US20200215068A1 (en) | Treatment of type i and type ii diabetes | |
KR100310665B1 (ko) | 피부질환치료용약제학적조성물 | |
JP2015038092A (ja) | 線維性障害を処置する方法 | |
JP2002533386A (ja) | 年齢関連器官機能不全および年齢関連疾患予防および寿命延長のための薬剤を製造するためのナトリウム/水素交換物質阻害剤の使用 | |
EP1386608B1 (en) | Remedial agent for glomerular disease | |
TW445261B (en) | A substituted thiophenylalkenylcarboxylic acid guanidide compound having the cellular Na<SP>+</SP>/H<SP>+</SP> exchanger inhibitory activity, the preparation processes and the pharmaceutical compositions thereof | |
WO2002064563A1 (de) | Neues benzoylguanidinsalz | |
EP1509216B1 (de) | Wirkstoffsalze und ester von 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol und 3-(3-dimethylamino-1-ethyl-1-hydroxy-2-methyl-propyl)-phenol | |
US7432296B2 (en) | Pharmaceutical formulations containing substituted 2-aryl-aminoacetic acid compounds and/or substituted 2-heteroaryl-aminoacetic acid compounds | |
TW387810B (en) | A pharmaceutical composition for treating polycystic kidney disease | |
CN115475158A (zh) | 一种萘腈类衍生物在制备抗肿瘤药物组合物中的应用 | |
CN108699043A (zh) | 大麻素受体介导化合物 | |
KR20040036724A (ko) | 1,2-디히드로-2-옥소-1,8-나프티리딘 유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050315 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081118 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090218 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090512 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090611 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120619 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |